VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)

The objective of this study is to evaluate if VTX958 is safe and effective in adult participants with active Psoriatic Arthritis. Approximately 195 eligible participants will take VTX958 Dose A, VTX958 Dose B, or matching placebo (no active drug) for 16 weeks. The study will include 16 weeks of treatment and a 30-day follow-up period.

Inclusion Criteria:Diagnosed with Psoriatic Arthritis for 6 months or more prior to ScreeningDocumented history or active signs of at least 1 confirmed lesion of plaque psoriasis and/or nail changes attributed to psoriasisActive PsA as defined by 3 or more swollen joints and 3 or more tender joints at Screening and Day 1Women must not be of childbearing potential or must agree to use a highly effective contraception during the study and for 30 days after the last dose of the study productMen with a partner who is of childbearing potential must agree to use condoms during the study and for 90 days after the last dose of study productExclusion Criteria:Has non-plaque psoriasis at Screening or Day 1Has inflammatory bowel disease or active uveitisHas a history of chronic or recurrent infectious diseaseHas a known immune deficiency or is immunocompromisedHas hepatitis B or hepatitis C infection, human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS), or active tuberculosis (TB) at screening